Celltrion Showcases Global Competitiveness of Remsima SC at AOCC&IMKASID

Encore Presentation of Phase 3 Clinical Results in Japanese Crohn's Disease Patients

Celltrion announced on June 25 that it will participate in the "2026 Asian Organization for Crohn’s & Colitis International Meeting and International Congress of the Korean Association for the Study of Intestinal Diseases (AOCC&IMKASID)," which will be held in Seoul from today until June 27, showcasing the global competitiveness of its autoimmune disease treatment, Remsima SC (ingredient: infliximab).

At this conference, Celltrion will deliver an encore presentation of the results from a phase 3 clinical trial involving 60 Japanese patients with Crohn’s disease (CD), which were recently released at the "2026 Digestive Disease Week (DDW)" in the United States. This study evaluated the efficacy and safety over a 44-week period after switching patients who had achieved clinical remission with the existing intravenous (IV) formulation of Remsima to the subcutaneous (SC) formulation, Remsima SC.

Incheon Songdo Celltrion Plant 2 exterior view. Photo by Hyunmin Kim

During the conference, its affiliate Celltrion Pharm will set up a large, exclusive booth and conduct extensive academic marketing, aiming to create strong synergy with Celltrion’s clinical achievements. On June 26, an expert session within the booth will share optimized usage strategies based on real-world prescription data of Remsima SC from overseas healthcare professionals.

On the same day, the "Celltrion Luncheon Symposium" will feature global key opinion leaders (KOLs) in the field of inflammatory bowel disease, Professor Silvio Danese of San Raffaele University in Italy and Professor Hong Sungno of Samsung Medical Center, who will serve as speakers. They will present on their real-world experience with subcutaneous infliximab prescriptions and the role of therapeutic drug monitoring in infliximab treatment, respectively.

Meanwhile, as of the fourth quarter of last year, Remsima SC held a 31% market share in the five major European countries (EU5), and its prescription volume in the United States—the world’s largest pharmaceutical market—grew by more than three times year-on-year in the first quarter of this year, further solidifying its position in the global market for autoimmune disease treatments.

A Celltrion official stated, "We will continue to secure robust clinical evidence in the global market to accelerate prescription expansion, and we will do our utmost so that more patients with autoimmune diseases can benefit from Remsima SC."

This content was produced with the assistance of AI translation services.